Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 113.93% ano a ano.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 2.29M.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 2.29M.
Subavaliada
O PE mais recente da empresa é -1.59, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 6.18M ações, um aumento de 16.17% em relação ao trimestre anterior.
Mantido por The Vanguard
O Super Investidor The Vanguard possui 0.00 ações desta empresa.